Replimune Group Inc (NASDAQ:REPL) – Analysts at SVB Leerink increased their Q4 2020 earnings estimates for shares of Replimune Group in a note issued to investors on Monday, March 23rd. SVB Leerink analyst J. Chang now forecasts that the company will post earnings of ($0.46) per share for the quarter, up from their previous forecast of ($0.47). SVB Leerink also issued estimates for Replimune Group’s FY2021 earnings at ($2.10) EPS and FY2022 earnings at ($2.15) EPS.

Other equities analysts also recently issued research reports about the company. BidaskClub downgraded Replimune Group from a “buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. ValuEngine upgraded Replimune Group from a “hold” rating to a “buy” rating in a research report on Friday, March 20th. Chardan Capital reissued a “buy” rating and issued a $28.00 target price on shares of Replimune Group in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $24.00 target price (down from $26.00) on shares of Replimune Group in a report on Tuesday, January 21st. Finally, Zacks Investment Research lowered Replimune Group from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $23.42.

Shares of REPL opened at $9.46 on Thursday. Replimune Group has a 12-month low of $8.58 and a 12-month high of $19.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 13.43 and a current ratio of 13.43. The company has a 50-day moving average of $14.10 and a two-hundred day moving average of $14.64.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10).

Hedge funds have recently added to or reduced their stakes in the company. Citigroup Inc. raised its position in shares of Replimune Group by 79.8% during the 4th quarter. Citigroup Inc. now owns 2,710 shares of the company’s stock valued at $39,000 after acquiring an additional 1,203 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Replimune Group in the 4th quarter valued at about $75,000. American International Group Inc. increased its stake in Replimune Group by 10.9% during the 4th quarter. American International Group Inc. now owns 8,124 shares of the company’s stock valued at $117,000 after buying an additional 799 shares during the period. California Public Employees Retirement System acquired a new position in Replimune Group during the 4th quarter valued at about $152,000. Finally, Marshall Wace LLP bought a new stake in shares of Replimune Group during the 4th quarter worth about $177,000. 60.10% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

See Also: What is an Initial Public Offering (IPO)?

Earnings History and Estimates for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.